<DOC>
	<DOCNO>NCT01168934</DOCNO>
	<brief_summary>This study open-label , randomize , 2-period , 2-treatment , 2-sequence , cross-over single-dose study test absolute bioavailability oral crizotinib formulation IV formulation healthy adult volunteer . Fourteen ( 14 ) subject enrol obtain least 12 evaluable subject complete study . Each subject receive two treatment ( A B ) washout period least 14 day treatment .</brief_summary>
	<brief_title>A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers</brief_title>
	<detailed_description>evaluate absolute bioavailability oral crizotinib IV crizotinib .</detailed_description>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Healthy male and/or female nonchildbearing potential subject age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . Body Mass Index ( BMI ) 17.5 30.5 kg/m^2 ; total body weight &gt; 50 kg ( 110 lb ) Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any condition possibly affect drug absorption ( eg , gastrectomy ) . A positive urine drug screen . History regular alcohol consumption exceed 14 drinks/week female 21 drinks/week male within 6 month screen . Treatment investigational drug within 30 day ( determined local requirement , whichever long ) 5 halflives precede first dose study medication . 12lead ECG demonstrate QTc &gt; 450 msec Screening . Pregnant nursing female ; female childbearing potential , include tubal ligation . Use prescription nonprescription drug dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication . Herbal supplement hormone replacement therapy must discontinue 28 day prior first dose study medication . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study . A positive serology Hepatitis B Hepatitis C. Subjects currently smoke .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>healthy volunteer</keyword>
	<keyword>crizotinib</keyword>
	<keyword>absolute bioavailability</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>